Drugs Made In America Acquisition Corp. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Drugs Made In America Acquisition Corp. and Power Analytics Global Corp amended their merger agreement (dated Sept 8, 2026) on October 13, 2026. Original closing valuation was $2.85B contingent on PAGC acquiring APQC Inc and UltraSolar IP. Amendment allows deal to close at standalone valuation of $1.71B if APQC acquisition not completed by November 1, 2026, with acquired assets added later at independently appraised value (capped at $2.85B ceiling). Previous fairness opinion firm terminated; replaced with sole evaluator Joel A. Gallo.
Why this rating
40% reduction in stated deal value materially alters transaction economics for $234.6M public company. Standalone valuation ($1.71B) is 7.3x company market cap—meaningful but contingency reduces near-term certainty and signals acquisition risk.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.